Free Trial

Verve Therapeutics (VERV) Stock Forecast & Price Target

Verve Therapeutics logo
$5.74 +0.58 (+11.24%)
(As of 12/20/2024 05:31 PM ET)

Verve Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
4

Based on 4 Wall Street analysts who have issued ratings for Verve Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 4 have given a buy rating for VERV.

Consensus Price Target

$25.75
348.61% Upside
According to the 4 analysts' twelve-month price targets for Verve Therapeutics, the average price target is $25.75. The highest price target for VERV is $40.00, while the lowest price target for VERV is $14.00. The average price target represents a forecasted upside of 348.61% from the current price of $5.74.
Get the Latest News and Ratings for VERV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors.

Sign Up

VERV Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.75$25.75$26.00$34.25
Forecasted Upside348.61% Upside430.93% Upside417.93% Upside139.68% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

VERV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VERV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Verve Therapeutics Stock vs. The Competition

TypeVerve TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside348.61% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent VERV News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/6/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$29.00 ➝ $32.00+398.44%
11/6/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$20.00 ➝ $17.00+168.99%
11/6/2024HC Wainwright
2 of 5 stars
 Lower TargetBuy ➝ Buy$15.00 ➝ $14.00+119.44%
4/3/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$56.00 ➝ $40.00+378.47%
11/13/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
9/13/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$22.00+63.45%
8/15/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$56.00 ➝ $55.00+222.20%
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$31.00+72.22%
8/8/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Jubinville
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:44 AM ET.


VERV Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Verve Therapeutics is $25.75, with a high forecast of $40.00 and a low forecast of $14.00.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VERV shares.

According to analysts, Verve Therapeutics's stock has a predicted upside of 348.61% based on their 12-month stock forecasts.

Verve Therapeutics has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, and Royal Bank of Canada in the past 90 days.

Analysts like Verve Therapeutics more than other "medical" companies. The consensus rating for Verve Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VERV compares to other companies.


This page (NASDAQ:VERV) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners